✦ LIBER ✦

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Scribed by Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Keizo Sugimachi; Kiyohiko Dohi; Yasuo Nomura; Yasumasa Monden; Yuzo Hamada; Tadaoki Morimoto; Nobuya Ogawa

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 714 KB
Volume: 70
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19921115)70:10<2475::aid-cncr2820701014>3.0.co;2-p

No coin nor oath required. For personal study only.

✦ Synopsis

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a biologic response modifier, to MMC + FT chemotherapy for patients with ERnegative tumors in operable Stage IIA, IIB, and IIIA cancer. The doses used were 20 mg of oral TAM daily, 600 mg of oral FT daily, and 3 g of oral PSK daily for 2 years. Intravenous MMC (13 mg/m2) was given on the day of operation.

A total of 967 patients were entered and randomized by stratification based on ER status and staging (1978 International Union Against Cancer [UICC] cri-Methods.

📜 SIMILAR VOLUMES

Randomized trial to evaluate the additio

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

✍ James N. Ingle; Lloyd K. Everson; H. Sam Wieand; Stephen A. Cullinan; Lester E. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 787 KB

Evaluation of the worth of Corynebacteri

Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight-year results from the national surgical adjuvant breast and bowel project B-10

✍ Bernard Fisher; Ann Brown; Norman Wolmark; Edwin R. Fisher; Carol Redmond; D. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

During the 1970s, information obtained from animal tumor models and from patients with a spectrum of solid tumors indicated the worth of a variety of immunostimulating agents. These findings provided a biological and clinical rationale for conducting randomized trials to evaluate the worth of those

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views